This study is not accepting new patients

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

a study on Lung Cancer Non-Small Cell Lung Cancer Thyroid Cancer Colon Cancer Colorectal Cancer Breast Cancer Pancreatic Cancer Solid Tumor

Summary

at UCLA UCSD UCSF
study started
Lyudmia Bazhenova, MD(ucsd)Alain Algazi, MD(ucsf)Mykola Onshchenko(ucla)

Description

Summary

Expanded access for patients with cancer with RET activation who are ineligible for an ongoing LOXO-292 clinical trial or have other considerations that prevent access to LOXO-292 through an existing clinical trial.

Details

N/A for expanded access

Keywords

Non Small Cell Lung Cancer Medullary Thyroid Cancer Colon Cancer Breast Cancer Pancreatic Cancer Papillary Thyroid Cancer Other Solid Tumors With Evidence of Activating RET Alteration Thyroid Neoplasms Thyroid Cancer, Papillary Thyroid Diseases LOXO-292

Eligibility

You can join if…

  • Diagnosis of cancer with RET activation, who are not eligible for an ongoing LOXO-292 clinical trial and are medically suitable for treatment with LOXO-292

You CAN'T join if...

  • Currently enrolled in an ongoing clinical study of LOXO-292 or another RET inhibitor

Locations

  • UC San Diego Moores Cancer Center
    La Jolla California 92093 United States
  • UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco California 94158 United States
  • Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center
    Torrance California 90502 United States
  • UCI Health - Chao Family Comprehensive Cancer Center
    Orange California 92868 United States

Lead Scientists

  • Lyudmia Bazhenova, MD (ucsd)
    Dr. Bazhenova’s clinical practice and research concentrate on lung cancer, particularly as this relates to females and non-smokers. She actively participates in cooperative group trials, and takes an active role in designing and implementing clinical investigations, including phase II studies and correlative science projects with several UCSD investigators.
  • Alain Algazi, MD (ucsf)
    Associate Professor, Medicine. Authored (or co-authored) 55 research publications
  • Mykola Onshchenko (ucla)

Details

Status
not accepting new patients
Start Date
Sponsor
Loxo Oncology, Inc.
ID
NCT03906331
Study Type
Expanded Access
Last Updated